| Date Filed | Type | Description |
| 06/15/2023 |
4
| Smith Julie (Director) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 19,441 options to buy
@ $12.46, valued at
$242.2k
|
|
| 06/02/2023 |
4
| Smith Julie (Director) has filed a Form 4 on EXELIXIS, INC.|
Txns:
| Granted 44,087 options to buy
@ $19.39, valued at
$854.8k
|
|
| 06/08/2022 |
4
| Smith Julie (Director) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 21,000 options to buy
@ $12.96, valued at
$272.2k
|
|
| 05/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/25/2021 |
4
| Smith Julie (Director) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 11,650 options to buy
@ $40.37, valued at
$470.3k
|
|
| 05/28/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/05/2020 |
4
| Smith Julie (Director) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 29,555 options to buy
@ $26.53, valued at
$784.1k
|
|
| 06/05/2020 |
3
| Smith Julie (Director) has filed a Form 3 on Stoke Therapeutics, Inc. |
| 05/22/2020 |
4
| Smith Julie (Director) has filed a Form 4 on EXELIXIS, INC.|
Txns:
| Granted 15,538 shares
@ $0 |
|
| 01/15/2020 |
4
| Smith Julie (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Disposed/sold 18,000 options to buy
@ $17.85, valued at
$321.3k
Disposed/sold 9,000 options to buy
@ $0
Disposed/sold 10,000 options to buy
@ $38.65, valued at
$386.5k
Disposed/sold 16,200 options to buy
@ $24.74, valued at
$400.8k
|
|
| 05/24/2019 |
4
| Smith Julie (Director) has filed a Form 4 on EXELIXIS, INC.|
Txns:
| Granted 42,641 options to buy
@ $19.77, valued at
$843k
|
|
| 02/08/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/08/2018 |
4
| Smith Julie (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $38.65, valued at
$386.5k
|
|
| 05/24/2018 |
4
| Smith Julie (Director) has filed a Form 4 on EXELIXIS, INC.|
Txns:
| Granted 31,167 options to buy
@ $20.5, valued at
$638.9k
|
|
| 10/10/2017 |
4
| Smith Julie (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Granted 9,000 options to buy
@ $26.01, valued at
$234.1k
|
|
| 05/26/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 02/24/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 01/05/2017 |
4
| Smith Julie (Director) has filed a Form 4 on Audentes Therapeutics, Inc. |
| 12/13/2016 |
3
| Smith Julie (Director) has filed a Form 3 on Audentes Therapeutics, Inc. |
| 10/26/2016 |
4
| Smith Julie (President and CEO) has filed a Form 4 on Raptor Pharmaceutical Corp|
Txns:
| Unknown transaction of 45,759 shares
@ $9, valued at
$411.8k
Disposed/sold 64,179 shares
@ $9, valued at
$577.6k
Disposed/sold 152,050 options to buy
@ $5.27, valued at
$801.3k
Disposed/sold 175,000 options to buy
@ $8.13, valued at
$1.4M
Disposed/sold 240,595 options to buy
@ $3.74, valued at
$899.8k
|
|
| 09/26/2016 |
4
| Smith Julie (Director) has filed a Form 4 on EXELIXIS, INC.|
Txns:
| Granted 763 shares
@ $0
Granted 26,000 options to buy
@ $14.74, valued at
$383.2k
|
|
| 09/26/2016 |
3
| Smith Julie (Director) has filed a Form 3 on EXELIXIS, INC. |
| 02/11/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 09/12/2012 |
4
| Smith Julie (EVP, Strategy and COO) has filed a Form 4 on Raptor Pharmaceutical Corp|
Txns:
| Granted 190,000 options to buy
@ $5.27, valued at
$1M
|
|
| 09/12/2012 |
3
| Smith Julie (EVP, Strategy and COO) has filed a Form 3 on Raptor Pharmaceutical Corp |